We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hospira Launches Phase III Trial For Biosimilar of Amgen’s Epogen
Hospira Launches Phase III Trial For Biosimilar of Amgen’s Epogen
January 17, 2012
Hospira has begun enrolling patients in a Phase III trial for a U.S. biosimilar of Amgen’s Epogen with results expected next year.